Efficacy of entecavir versus tenofovir disoproxil fumarate in preventing hepatocellular carcinoma-The jury is out

被引：0
|
作者：
Peng, Cheng-Yuan [1 ,2 ,3 ]
机构：
[1] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, Taichung, Taiwan
[2] China Med Univ, Sch Med, Taichung, Taiwan
[3] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, 2 Yude Rd, Taichung 404332, Taiwan
来源：
ADVANCES IN DIGESTIVE MEDICINE | 2024年 / 11卷 / 01期
关键词：
CHRONIC HEPATITIS-B; RISK;
D O I：
10.1002/aid2.13391
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：5 / 7
页数：3
相关论文
共 50 条
  • [1] Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma
    Murata, Kazumoto
    Mizokami, Masashi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (05) : 683 - 691
  • [2] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Shao-Ming Chiu
    Kuo-Chin Chang
    Tsung-Hui Hu
    Chao-Hung Hung
    Jing-Houng Wang
    Sheng-Nan Lu
    Chien-Hung Chen
    Digestive Diseases and Sciences, 2023, 68 : 665 - 675
  • [3] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Chiu, Shao-Ming
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Chen, Chien-Hung
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 665 - 675
  • [4] Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
    Ha, Yeonjung
    Chon, Young Eun
    Kim, Mi Na
    Lee, Joo Ho
    Hwang, Seong Gyu
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [5] Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
    Yeonjung Ha
    Young Eun Chon
    Mi Na Kim
    Joo Ho Lee
    Seong Gyu Hwang
    Scientific Reports, 10
  • [6] Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B?
    van Velsen, Lisa M.
    Sonneveld, Milan J.
    van Erpecum, Karel J.
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (06) : 919 - 922
  • [7] AN EFFICACY OF CONTINUING TENOFOVIR DISOPROXIL FUMARATE VERSUS SWITCHING ENTECAVIR TO TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT OF CHRONIC HEPATITIS B PATIENTS: 5-YEAR FOLLOW UP
    Ungtrakul, Teerapat
    Chiersilpa, Kunsuda
    Yingcharoen, Kesinee
    Jiraphairot, Suppawat
    Sangwipasnapaporn, Worrawat
    Dechma, Jiraporn
    Chunnuan, Pitchayachuda
    Kusuman, Pattama
    Pothijaroen, Charinthip
    Tawpa, Jantarika
    Hankla, Pimprapa
    Numahan, Apichayaporn
    Pongpun, Wanwisa
    Soonklang, Kamonwan
    GUT, 2022, 71 : A72 - A72
  • [8] Entecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis B-related liver cirrhosis
    Lin, Yu-Hung
    Lai, Huang-Lun
    Wang, Chun-Hsiang
    Chang, Kuo-Kuan
    Mo, Lein-Ray
    Lin, Ruey-Chang
    ADVANCES IN DIGESTIVE MEDICINE, 2024, 11 (01) : 16 - 23
  • [9] Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
    Sara M. Tony
    Mohamed E. A. Shaaban
    Ahmed I. M. Mohamed
    Mohamed E. A. Abdelrahim
    Beni-Suef University Journal of Basic and Applied Sciences, 11
  • [10] Tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma compared to entecavir in patients with chronic hepatitis B
    Lee, Hye Won
    Kim, Seung Up
    HEPATOMA RESEARCH, 2022, 8
12345